CRISPR Therapeutics AG Stock price

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-04 pm EST Intraday chart for CRISPR Therapeutics AG 5-day change 1st Jan Change
71.51 USD +4.17% -0.14% +75.92%
Sales 2023 * 276M Sales 2024 * 148M Capitalization 5.45B
Net income 2023 * -290M Net income 2024 * -448M EV / Sales 2023 *
14,6x
Net cash position 2023 * 1.42B Net cash position 2024 * 1.26B EV / Sales 2024 *
28,3x
P/E ratio 2023 *
-19,1x
P/E ratio 2024 *
-11,5x
Employees 458
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.17%
1 week+2.20%
Current month+7.16%
1 month+40.24%
3 months+41.52%
6 months+10.02%
Current year+75.92%
More quotes
1 week
63.39
Extreme 63.39
73.55
1 month
48.55
Extreme 48.5501
76.19
Current year
37.55
Extreme 37.55
76.19
1 year
37.55
Extreme 37.55
76.19
3 years
37.55
Extreme 37.55
220.20
5 years
22.22
Extreme 22.2201
220.20
10 years
11.63
Extreme 11.63
220.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 2015
Director of Finance/CFO 39 Mar. 13
Chief Tech/Sci/R&D Officer 49 2022
Members of the board TitleAgeSince
Director/Board Member 65 2020
Director/Board Member 45 2015
Director/Board Member 46 2015
More insiders
Date Price Change Volume
23-12-04 71.51 +4.17% 2,815,394
23-12-01 68.65 +2.88% 3,675,377
23-11-30 66.73 -3.42% 2,515,802
23-11-29 69.09 -2.22% 2,215,093
23-11-28 70.66 -1.33% 1,861,191

Delayed Quote Nasdaq, December 04, 2023 at 04:00 pm EST

More quotes
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
71.51USD
Average target price
88.36USD
Spread / Average Target
+23.56%
Consensus
  1. Stock
  2. Equities
  3. Stock CRISPR Therapeutics AG - Nasdaq
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer